The Power demonstrated with EYLEA—Proven Results Across All Approved Indications1

EYLEA indications are backed by 7 pivotal studies evaluating BCVA as measured by ETDRS* letters in over 3000 patients: VIEW 1 and VIEW 2 (Wet AMD) at 52 weeks, VISTA and VIVID (DME and DR in Patients with DME) at 52 and 100 weeks, GALILEO and COPERNICUS (MEfCRVO) at 24 weeks, and VIBRANT (MEfBRVO) at 24 weeks.1 When starting a patient on EYLEA, consider the body of evidence demonstrating proven results.1

Empower your EYLEA treatment decisions from the start with RESULTS from the 7 pivotal trials1

  • *Best-corrected visual acuity as measured by Early Treatment Diabetic Retinopathy Study
  • anti-VEGF = anti–Vascular Endothelial Growth Factor
  • AMD = Age-related Macular Degeneration
  • BCVA = Best-Corrected Visual Acuity
  • DME = Diabetic Macular Edema
  • DR = Diabetic Retinopathy
  • ETDRS = Early Treatment Diabetic Retinopathy Study
  • RVO = Retinal Vein Occlusion (includes Branch Retinal Vein Occlusion [BRVO] and Central Retinal Vein Occlusion [CRVO])

No Matter What the Approved Indication, EYLEA Has More Than 90% First-Line Coverage Nationally*,2

First-line coverage means direct access to EYLEA—access that supports your treatment choice from the start.2 And, if patients need help paying for treatment, EYLEA4U® can assist in finding support options to help them with the cost.

*Individual patient coverage is subject to a patient's specific plan.

In My Eyes by Regeneron logo

Experience what certain retinal diseases can be like in virtual reality

A powerful teaching tool to use with your patients and caregivers, this unique app lets the user experience retinal disease symptoms firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

  • Available on the App Store
  • Android app on Google play
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information Important Prescribing Information

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. May 2017.
  2. Data on file. Zitter Health Insights Policy Access & Tracking Tool. August 2016.